Literature DB >> 11474009

Burkholderia cepacia complex infection in Italian patients with cystic fibrosis: prevalence, epidemiology, and genomovar status.

A Agodi1, E Mahenthiralingam, M Barchitta, V Gianninò, A Sciacca, S Stefani.   

Abstract

The prevalence, epidemiology, and genomovar status of Burkholderia cepacia complex strains recovered from Italian cystic fibrosis (CF) patients were investigated using genetic typing and species identification methods. Four CF treatment centers were examined: two in Sicily, one in central Italy, and one in northern Italy. B. cepacia complex bacteria were isolated from 59 out of 683 CF patients attending these centers (8.6%). For the two geographically related treatment centers in Sicily, there was a high incidence of infection caused by a single epidemic clone possessing the cblA gene and belonging to B. cepacia genomovar III, recA group III-A, closely related to the major North America-United Kingdom clone, ET12; instability of the cblA sequence was also demonstrated for clonal isolates. In summary, of all the strains of B. cepacia encountered in the Italian CF population, the genomovar III, recA group III-A strains were the most prevalent and transmissible. However, patient-to-patient spread was also observed with several other genomovars, including strains of novel taxonomic status within the B. cepacia complex. A combination of genetic identification and molecular typing analysis is recommended to fully define specific risks posed by the genomovar status of strains within the B. cepacia complex.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11474009      PMCID: PMC88256          DOI: 10.1128/JCM.39.8.2891-2896.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

1.  Consensus guidelines for appropriate use and evaluation of microbial epidemiologic typing systems.

Authors:  M. J. Struelens
Journal:  Clin Microbiol Infect       Date:  1996-08       Impact factor: 8.067

Review 2.  Genomic complexity and plasticity of Burkholderia cepacia.

Authors:  T G Lessie; W Hendrickson; B D Manning; R Devereux
Journal:  FEMS Microbiol Lett       Date:  1996-11-01       Impact factor: 2.742

Review 3.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

4.  Differentiation of Burkholderia species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gene and application to cystic fibrosis isolates.

Authors:  C Segonds; T Heulin; N Marty; G Chabanon
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

5.  DNA-Based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III.

Authors:  E Mahenthiralingam; J Bischof; S K Byrne; C Radomski; J E Davies; Y Av-Gay; P Vandamme
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

6.  Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov.

Authors:  P Vandamme; B Holmes; M Vancanneyt; T Coenye; B Hoste; R Coopman; H Revets; S Lauwers; M Gillis; K Kersters; J R Govan
Journal:  Int J Syst Bacteriol       Date:  1997-10

7.  Epidemiology of Burkholderia cepacia infection in patients with cystic fibrosis: analysis by randomly amplified polymorphic DNA fingerprinting.

Authors:  E Mahenthiralingam; M E Campbell; D A Henry; D P Speert
Journal:  J Clin Microbiol       Date:  1996-12       Impact factor: 5.948

8.  The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain.

Authors:  L Sun; R Z Jiang; S Steinbach; A Holmes; C Campanelli; J Forstner; U Sajjan; Y Tan; M Riley; R Goldstein
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

9.  Linkage analysis of geographic and clinical clusters in Pseudomonas cepacia infections by multilocus enzyme electrophoresis and ribotyping.

Authors:  W M Johnson; S D Tyler; K R Rozee
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

10.  Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland.

Authors:  T L Pitt; M E Kaufmann; P S Patel; L C Benge; S Gaskin; D M Livermore
Journal:  J Med Microbiol       Date:  1996-03       Impact factor: 2.472

View more
  27 in total

1.  Molecular typing of, and distribution of genetic markers among, Burkholderia cepacia complex isolates from Brazil.

Authors:  Maria G Detsika; John E Corkill; Marcelo Magalhães; Kerry J Glendinning; C Anthony Hart; Craig Winstanley
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

Review 2.  Recent advances in cross-infection in cystic fibrosis: Burkholderia cepacia complex, Pseudomonas aeruginosa, MRSA and Pandoraea spp.

Authors:  Andrew M Jones; A Kevin Webb
Journal:  J R Soc Med       Date:  2003       Impact factor: 5.344

3.  Direct PCR detection of Burkholderia cepacia complex and identification of its genomovars by using sputum as source of DNA.

Authors:  Pavel Drevínek; Hana Hrbácková; Ondrej Cinek; Jana Bartosová; Otakar Nyc; Alexandr Nemec; Petr Pohunek
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

Review 4.  A decade of Burkholderia cenocepacia virulence determinant research.

Authors:  Slade A Loutet; Miguel A Valvano
Journal:  Infect Immun       Date:  2010-07-19       Impact factor: 3.441

5.  Multilocus sequence typing scheme that provides both species and strain differentiation for the Burkholderia cepacia complex.

Authors:  Adam Baldwin; Eshwar Mahenthiralingam; Kathleen M Thickett; David Honeybourne; Martin C J Maiden; John R Govan; David P Speert; John J Lipuma; Peter Vandamme; Chris G Dowson
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

6.  Exceptionally high representation of Burkholderia cepacia among B. cepacia complex isolates recovered from the major Portuguese cystic fibrosis center.

Authors:  Mónica V Cunha; Ana Pinto-de-Oliveira; Luís Meirinhos-Soares; Maria José Salgado; José Melo-Cristino; Susana Correia; Celeste Barreto; Isabel Sá-Correia
Journal:  J Clin Microbiol       Date:  2007-03-14       Impact factor: 5.948

7.  Transmission of Burkholderia cepacia complex: evidence for new epidemic clones infecting cystic fibrosis patients in Italy.

Authors:  S Campana; G Taccetti; N Ravenni; F Favari; L Cariani; A Sciacca; D Savoia; A Collura; E Fiscarelli; G De Intinis; M Busetti; A Cipolloni; A d'Aprile; E Provenzano; I Collebrusco; P Frontini; G Stassi; M Trancassini; D Tovagliari; A Lavitola; C J Doherty; T Coenye; J R W Govan; P Vandamme
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

Review 8.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

9.  Epidemiology and clinical course of Burkholderia cepacia complex infections, particularly those caused by different Burkholderia cenocepacia strains, among patients attending an Italian Cystic Fibrosis Center.

Authors:  Graziana Manno; Claudia Dalmastri; Silvia Tabacchioni; Peter Vandamme; Renata Lorini; Laura Minicucci; Luca Romano; Alessandro Giannattasio; Luigi Chiarini; Annamaria Bevivino
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

10.  Comparative assessment of genotyping methods for epidemiologic study of Burkholderia cepacia genomovar III.

Authors:  Tom Coenye; Theodore Spilker; Alissa Martin; John J LiPuma
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.